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Glaucoma
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PURPOSE. The purpose of this study was to analyze the neuroprotective effect of an a7 nAChR
agonist, PNU-282987, using an in vivo model of glaucoma in Long Evans rats.
METHODS. One eye in each animal was surgically manipulated to induce glaucoma in control
untreated animals and in animals that were treated with intravitreal injections of PNU-282987.
To induce glaucoma-like conditions, 0.05 mL of 2 M NaCl was injected into the episcleral
veins of right eyes in each rat to create scar tissue and increase intraocular pressure. The left
eye in each rat acted as an internal control. One month following NaCl injection, rats were
euthanized, retinas were removed, flatmounted, fixed, and nuclei were stained with cresyl
violet or RGCs were immunostained with an antibody against Thy 1.1 or against Brn3a.
Stained nuclei in the RGC layer and labeled RGCs in NaCl-injected retinas were counted and
compared with cell counts from untreated retinas in the same animal.
RESULTS. NaCl injections into the episcleral veins caused a significant loss of cells by an average
of 27.35% (62.12 SEM) in the RGC layer within 1 month after NaCl injection, which
corresponded to a significant loss of RGCs. This loss of RGCs was eliminated if 5 lL of 100 lM
PNU-282987 was injected into the right eye an hour before NaCl injection.
CONCLUSIONS. The results from this study support the hypothesis that the a7 agonist, PNU282987, has a neuroprotective effect in the rat retina. PNU-282987 may be a viable candidate
for future therapeutic treatments of glaucoma.
Keywords: neuroprotection, glaucoma, retinal ganglion cells

laucoma is a degenerative retinal disease and is characterized by optic neuropathy and cupping of the optic disk,
degeneration of retinal ganglion cells (RGCs), and eventual
visual field loss. In several in vitro models of glaucoma, death of
RGCs is induced by excessive neurotransmitters that trigger
excitotoxicity and apoptosis.1–6 Recently, a great deal of
research has explored agents and mechanisms that provide
neuroprotection against excitotoxicity.7–9 In previous studies
from this lab, acetylcholine (ACh) and nicotine have been found
to be neuroprotective in the retina and act to prevent
glutamate-induced excitotoxicity in an isolated cultured pig
and rat RGC preparation.10,11 Other pharmacological studies
using pig- and rat-cultured RGCs have demonstrated that
activation of specific a7 nAChRs are linked to this neuroprotective effect.11,12 However, it is unclear if activation of a7
nAChRs have any significant neuroprotective role against RGC
loss normally associated with glaucoma. To address this issue,
the a7 nicotinic agonist, PNU-282987, was analyzed in an in
vivo rat model of glaucoma to test the hypothesis that
introduction of the a7 nicotinic agonist, PNU-282987, can
significantly reduce the loss of cells in the RGC layer that is
normally associated with glaucoma.
Previous studies from our lab have implicated a7 nAChRs on
RGCs as a potential target for neuroprotection in the retina and
RGCs against glutamate-induced excititoxicity.10,12–14 In these
in vitro studies, RGCs from pig or rat11 were isolated from all
other retinal tissue and cultured to demonstrate glutamate-

induced excitotoxicity and ACh and nicotine-induced neuroprotection. Evidence was provided that excitotoxicity, induced
with 500 lM glutamate, was significantly reduced in a dosedependent manner if relatively low concentrations of ACh or
nicotine were applied to isolated cells before glutamate. When
the a7 receptor nicotinic antagonists, a-Bgt or MLA, were
applied before ACh or nicotine, the neuroprotective effect of
ACh and nicotine was significantly reduced.
Further in vitro studies using the a7 nAChR agonist PNU282987 on isolated rat RGCs support the hypothesis that
neuroprotection against glutamate-induced excitotoxicity is
mediated through a7 nAChRs.11 Binding studies with rat
chimera cells and electrophysiology studies in rats have
demonstrated that PNU-282987 is a potent specific agonist for
a7 nAChRs.15 These binding studies have shown that PNU282987 can displace MLA, an a7 antagonist. Using rat
hippocampal neurons, application of the PNU compounds
cause currents through a7-nAChR channels in a dose-dependent matter. This effect was blocked with MLA.15 As a result of
these previous studies, PNU-282987 was used in this study to
understand the role of the a7-nACh receptor as a neuroprotective agent against loss of RGCs in a glaucomatous rat model
without worrying about cross-reactivity or cross-binding with
other nAChRs that may make the analysis and interpretation of
data difficult.
The method used to induce glaucoma in Long Evans rats is
based on a method of injecting 2 M hypertonic saline into the
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episcleral veins of the eye.16 The 2 M salt solution causes
scarring in the trabecular meshwork and decreases the outflow
of aqueous humor. This results in a gradual increase of
intraocular pressure and loss of RGCs to mimic glaucoma-like
conditions in the retina.16 In this study, this model of glaucoma
was used to demonstrate the neuroprotective effect of PNU282987 to prevent the loss of RGCs normally associated with
the model. The results from this study open up possibilities for
a new treatment for glaucoma that does not solely deal with
treating IOP, which is the sole target for all current glaucoma
treatments. Using a7-nAChR agonists in conjunction with
already existing treatments could provide an additional
therapeutic benefit or could lead to preventative care in
patients at high risk for developing glaucoma.

MATERIALS

AND

METHODS

Adult male and female Long Evans rats aged 3 months
(breeding colony, WMU) were used for these in vivo
experiments as this particular outbred strain was also used in
previous in vitro studies performed in this lab.11 Each animal
was kept in the animal colony prior to experiments. All animals
were treated and eventually euthanized according to IACUC
protocols. Animal treatment was in adherence to the ARVO
Statement for the Use of Animals in Ophthalmic and Vision
Research.

Inducing Glaucoma
Before injecting NaCl into the episcleral veins to induce
glaucoma-like conditions, adult Long Evans rats were anesthetized with 0.1 mL/100 g KAX via intraperitoneal injections
until no reflexes were observed. KAX is a combination cocktail
consisting of 5 mL ketamine (100 mg/mL; DVM, Dallas, TX);
2.5 mL xylazine (20 mg/mL; Sigma-Aldrich, St. Louis, MO); 1
mL acepromazine (10 mg/mL; Vet Depot, Fort Payne, AL); and
0.5 mL sterile water. A topical anesthetic of procaine
hydrochloride was applied to the cornea before any NaCl
injection into the episcleral veins. To expose the targeted
episcleral veins and to restrict movement of the eye, a
hemostat was used to pinch the bottom eyelid, which caused
the eye and corresponding episcleral veins to bulge out of the
eye socket to expose the episcleral veins. The conjunctiva was
incised with fine scissors to further expose the vein, under a
dissecting microscope. To inject 50 lL of 2 M hypertonic saline
into the right episcleral veins, a 3-mm long glass microneedle, 3
to 5 um in diameter, was attached to a piece of tapered
polyethylene tubing. The microneedle was pulled using a
vertical electrode puller (NARISHIGE Group; Tokyo, Japan),
beveled and inserted into a 23-gauge needle with the tip filed
off, and attached to tubing attached to a 1 mL syringe. When
the salt was injected into the episcleral veins, the veins
blanched as the saline was distributed through the circulatory
system. This was taken as confirmation that the injection of 2
M NaCl occurred. Visualization of blanching in the episcleral
veins correlated directly with significant loss of cells from the
RGC layer after 1 month and an increase of intraocular
pressure (IOP). The rats were kept under observation until
fully awake before they were transported back to the animal
colony. The injections of 2 M hypertonic saline were typically
performed in the right eye of most rats. The left eye typically
acted as an internal control.

IOP Measurements Using Tonometer
IOP measurements were obtained before NaCl injections to
obtain a baseline and after NaCl injections to verify an increase
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of IOP as a result of hypertonic injection. IOP measurements
were obtained from awake behaving rats using a tonometer
(Tono-Pen XL; Mentor O & O, Inc., Norwell, MA) according to
instructions outlined by Morrison et al.16 Rat eyes were
anesthetized with 1 drop of 0.5% proparacaine hydrochloride
into each eye before using the tonometer (Mentor O & O, Inc.).
Rats were loosely held in the experimenter’s hand during this
procedure and were rewarded with a piece of cereal (Cheerios;
General Mills, Minneapolis, MN) after obtaining measurements.
IOP measurements were obtained each day for 1 week before
NaCl injection and five times each week after NaCl injection
until the animals were killed.

Intravitreal Injection of Pharmacological Agents
For these studies, drugs were injected intravitreally into the
eye’s vitreous cavity in volumes of 5 lL using a syringe
(Hamilton Company, Reno, NV). The injection of various
concentrations of pharmacological agents included the a7
nicotinic agonist PNU-282987 (Sigma-Aldrich), or the a7
antagonist MLA (Tocris Bioscience, Minneapolis, MN). These
sterile agents were injected into the right eyes of animals
before NaCl injection that normally induced glaucoma-like
conditions. Based on results obtained from preliminary studies
and from in vitro results, intravitreal injections of PNU-282987
were applied 1 hour before NaCl injection to obtain maximal
effects. For inhibition studies, injections of MLA were applied 1
hour before intravitreal injection of PNU-282987 and 2 hours
before NaCl injection into the episcleral veins.

Labeling Cells in the RGC Layer
One month following intravitreal treatment and/or NaCl
injection into episcleral veins, rats were euthanized by CO2
asphyxiation and the retinas were removed after forming an
eyecup and after introducing a notch into the retina that was
used to maintain retinal orientation. Four incisions every 908
were made into the retinas in order to flatmount the retinas
onto small sylgard plates using cactus needles. This produced
four different retinal quadrants. One quadrant represented the
dorsal retina containing the highest density of RGCs in the
visual streak, while the other quadrants represented ventral,
nasal, and temporal regions of the retina (Fig. 1). The pinned
out retinas were then fixed with 10% formalin overnight at 48C.
Once fixed, some retinas were rinsed with PBS and transferred
to a pig skin gelatin-coated glass slide and cresyl violet was
used to stain cell nuclei according to standard procedures.
Other retinas were processed to directly label the glycoprotein Thy 1.1, found only in the plasma membrane of RGCs
in the retina,17 or by using the RGC specific nuclear marker
Brn3a.18,19 Once the retinas were flatmounted and fixed
overnight, the following day the retinas were rinsed with PBS,
incubated in 2% BSA in PBS containing 0.02% saponin for 30
minutes at room temperature to block non-specific binding,
then incubated in mouse anti-rat monoclonal antibody against
Thy 1.1 (1:300; Millipore Corp., Billerica, MA) or in rabbit antimouse polyclonal antibody against Brn3a (1:800; Millipore
Corp.) for 1 week at 48C in PBS containing 0.02% saponin.
After 1 week, the retinas were rinsed three times with PBS,
then incubated in AlexaFluor 594 (Life Technologies, Grand
Island, NY) secondary goat anti-mouse antibody (1:300) to
visualize the Thy 1.1 glycoprotein, or in AlexaFluor 594
secondary donkey anti-rabbit (1:300; Life Technologies) for
visualization of Brn3a. Secondary antibodies were applied for 5
days at 48C. Following incubation in secondary antibody, the
retinas were transferred to glass slides for viewing and imaging.
In control studies, experiments were conducted to display
specificity of the antibodies used. In some negative control
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experiments, large RGCs were processed with the primary
antibodies omitted, while other experiments substituted
nonimmune mouse immunoglobulin (dilution: 0.1–1.0 lg/
mL) for the antibodies. In other experiments, preabsorption
controls were performed where the primary antibody and
antigens were added together before applying to tissue. No
significant epifluorescence was observed under any of these
conditions.
Once mounted, the stained tissues were imaged throughout
the ganglion cell layer in each of the four defined retinal
quadrants using 1-lm increments using the capabilities of a
Zeiss confocal microscope with a rhodamine filter using the
optic nerve head and the orientation of the retina. In each
quadrant, one series of images were obtained from the retina 4
mm from the optic nerve head (ONH). For some studies, a
second series of images were obtained 2 mm from the ONH.
The cell bodies in the RGC layer stained with cresyl violet were
opaque and could easily be counted. The process produced
good contrast between cell nuclei and background, allowing
for easy quantification. For RGCs that were immunostained
with a fluorescently labeled antibody against Thy 1.1,
fluorescence was observed in the plasma membrane of the
RGCs as well as in the RGC axons. Anti-Brn3a stained RGC
nuclei.
When analyzing RGCs labeled with anti-Thy 1.1, quantification of RGCs from each quadrant was formulated using a 100lm2 frame. The position of this frame was placed to avoid axon
fascicle interference. Preliminary studies used multiple placements of the 100-lm2 frame to determine how reproducible
the quantification method was. There were significant
differences in RGC counts if only two or three frames were
used to quantify RGCs. However, if four, six or eight frames
were evenly distributed around the ONH 4 mm from the ONH,
the average RGC counts were significantly similar. As a result, a
series of images were obtained from each of the four retinal
quadrants 4 mm or 2 mm from the ONH for RGC quantification
and counts were averaged. For quantification of RGC nuclei
labeled with anti-Brn3a, axon fascicles were not labeled and
each quadrant could be analyzed using a 2-mm2 frame in the
four retinal quadrants 4 mm from the ONH. RGCs were
counted using image analysis software (MetaMorph; Molecular
Devices, LLC, Sunnyvale, CA), averaged, and compared with
internal controls.
To validate this counting method, a blind study was
performed using six different student participants. Students
were asked to blind count the number of RGCs labeled with
the antibody against Thy 1.1 or with the antibody against Brn3a
using the procedure described above. Each student counted
similar numbers of RGCs (n ¼ 20 retinas). There was no
significant difference in RGC counts when students counted
cells labeled with anti-Thy 1.1 or when cells were labeled with
anti-Brn3a.

LC/MS/MS Analysis
Liquid chromatography-quadrupole mass spectrometry (LC/
MS/MS) was performed on retina removed from euthanized
Long Evans rats at various time points following intravitreal
injections of three different concentrations of PNU-282987.
Specifically, retinas were removed from euthanized Long Evans
rats 1, 2, 4, 8, and 12 hours after injecting 5 lL of 10 lM, 100
lM, or 1 mM PNU-282987 into the rat’s vitreous cavity. These
time intervals corresponded to those that were done in the
rabbit retina with the same compound (Linn DM, et al. IOVS
2011:ARVO E-Abstract 3237). Removed retinas were rinsed to
remove any residual PNU-282987, weighed, and sent to the
Southwest Michigan Innovation Center (Kalamazoo, MI) for
LC/MSMS detection of PNU-282987. Analysis was performed
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using standard procedures on a mass spectrometer (Micromass
Quattro Micro triple quadrupole mass spectrometer; Waters
Corp., Milford, MA) using positive ion electrospray ionization.
A capillary HPLC (CapLC System; Waters Corp.) was configured for online SPE.

Data Analysis
All cell counts were compared with the internal control counts
for each experiment. Student’s t-tests were used for single
comparisons, and one-way ANOVA was used for multiple
comparisons to statistically measure cellular loss with Tukey’s
post hoc tests using statistical software (Prism GraphPad
version 4.0; GraphPad Software Inc., San Diego, CA) and a
statistics package (Minitab; Pennsylvania State University,
University Park, Pennsylvania). For normalized data, statistical
analysis was performed using Kruskall-Wallis nonparametric
analysis of variance with post hoc comparisons (Dunn’s test). A
P value <0.05 represented significance. Graphs were plotted
with statistical software (GraphPad Software, Inc.).

RESULTS
Flatmounted Retina
Figure 1 demonstrates where images were obtained from
flatmounted retinas. The retina displayed in Figure 1 was
removed from a rat eyecup and positioned in a sylgard dish
with the RGC layer facing up. The retina was then orientated
with the visual streak in the dorsal quadrant and four quadrants
were produced. Images were obtained 2 mm (white boxes)
and 4 mm (yellow boxes) from the optic nerve head in the
dorsal, nasal, temporal, and ventral quadrants. Great care was
taken to maintain the orientation of the retina throughout the
imaging process.

Cell Loss in the RGC Layer
The image in Figure 2 was obtained after a flatmounted retina
was processed with cresyl violet. Under the Zeiss confocal
microscope, all nuclei in cresyl violet–stained cells appeared
opaque. The image in Figure 2A was obtained from the left eye
of a rat, 4 mm from the ONH in the nasal quadrant. This eye
was untreated and acted as an internal control. The image in
Figure 2B was obtained from the right eye of the same rat, 4
mm from the ONH from the same region of the retina one
month after 50 lL of 2M NaCl was injected into the animal’s
episcleral veins. As seen in Figure 2B, there are fewer stained
nuclei in the RGC layer compared with the internal control
(Fig. 2A).
The number of stained cells in the RGC layer were counted
at 2- and 4-mm distances from the ONH in each of the four
quadrants and compared with internal controls. The bar graphs
in Figure 3 summarize the results of these experiments. Each
bar graph represents the average number of stained cell bodies
counted 4 mm from ONH and 2 mm from ONH throughout the
RGC layer. The part of the retina 4 mm from the ONH had an
average cell loss of 27.35% (62.12 SEM; n ¼ 12) from the RGC
layer 1 month after injecting 2 M NaCl hypertonic saline (Fig. 3,
left bar), compared with the retina 2 mm from the ONH, which
demonstrated an average of 20.01% (65.21 SEM; n ¼ 12) cell
loss (Fig. 3, right bar). As more cell loss in the periphery is
typically associated with glaucoma, all other experiments
counted cells 4 mm from the ONH.
The bar graphs in Figure 4 demonstrate that there is
significant cell loss from the RGC layer 1 month following NaCl
injection in Long Evans rats. Each bar in the figure represents
the average cell survival compared with the internal control
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FIGURE 3. Percent cell loss associated with glaucoma-inducing
procedure. This graph depicts the percent survival of cells in the
RGC layer at 200 and 4 mm from the ONH 1 month after the episcleral
veins were injected with hypertonic saline. Each bar was produced
using between 6 and 12 rat eyes. Asterisk represents significance from
internal untreated controls. Error bars represent SEM.

FIGURE 1. Flatmount retina. One month following NaCl injection, the
retina was removed and flatmounted onto a sylgard dish using cactus
needles with the RGC layer facing up. The yellow boxes represent the
areas of the retina where RGCs were counted (4 mm from the ONH),
while the white boxes represent a distance of 2 mm from the ONH.
The dotted lines represent retinal orientation maintained throughout
the experiments. d, dorsal; n, nasal; t, temporal; v, ventral.

month, hypertonic injections of saline into the episcleral vein
always caused a significant amount of cell loss in the RGC layer,
ranging between 18% and 27% if blanching occurred throughout the episcleral veins following the injection. Based on these
results, all rats in subsequent glaucoma-inducing experiments
were killed 1 month following NaCl injection and cell counts
were obtained 4 mm from the ONH.

Labeling RGCs In Vivo
retinas when animals were euthanized 1 and 2 weeks, and 1, 2,
and 4 months following the hypertonic injections. At the end
of each time interval, the animals were euthanized and the
retinas were removed, flatmounted, fixed, and stained with
cresyl violet. As can be seen by the summarized results in
Figure 4, significant loss of cells 4 mm from the ONH in the
RGC layer occurred 1 month following the NaCl injection and
there was no additional significant difference in the loss of cells
at 2 and 4 months compared to 1 month results. Though longer
studies were done at 5 and 6 months, (data not shown), at 1

Although careful consideration was given to cell counts from
specific regions in the RGC layer in vivo, cresyl violet stains all
cell bodies in the RGC layer. As displaced amacrine cells are
also found in the retinal ganglion cell layer,20,21 it is unlikely
that cell counts obtained with cresyl violet only represent the
RGC population. To determine what percentage of cells in the
RGC layer are represented by RGCs in these experiments,
some retinas were immunostained with an antibody against
Thy 1.1. Experimental rat eyes injected with hypertonic saline
were euthanized after 1 month and the retinas were removed,

FIGURE 2. Visualization of cell loss from RGC layer. The images in Figure 2 were taken 4 mm from the ONH and represent cells in the RGC layer
stained with cresyl violet. (A) Image obtained from the left control eye. (B) Image obtained 1 month after an injection of hypertonic saline. Both
images were taken from the same rat, from the equivalent retinal region and from the same depth in the RGC layer. Single-headed arrows indicate
stained nuclei in the RGC layer, while double-headed arrows point to defined axon tracks.
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FIGURE 4. Time-dependent effects following hypertonic injections.
Animals were euthanized at different time points after NaCl injection
and the loss of cells in the RGC layer were quantified in a timedependent manner. Each bar graph represents the average number of
cell bodies stained with cresyl violet that were counted in the RGC
layer after inducing glaucoma-like conditions with hypertonic saline
injections. Asterisk indicates significance from the untreated control.
Each bar graph was generated from between 6 to 12 animals. Error
bars represent SEM.

pinned on sylgard plates, and fixed. The flatmounted retinas
were then incubated with a monoclonal antibody against Thy
1.1 and secondarily labeled with AlexaFluor 594 goat antimouse IgG. Figure 5 represents images obtained 4 mm from the
ONH from the temporal quadrant after RGCs were stained with
the Thy 1.1 antibody. Figure 5A is an image obtained from an
untreated control retina. An average of 8.22% (62.21) of cells
in images obtained 4 mm from the ONH in the RGC layer did
not label with the primary antibody (n ¼ 25).
Figure 5B was obtained from the same animal’s right eye
from the same temporal retinal location 1 month after NaCl
injection. As shown in this image, the hypertonic saline
injection resulted in fewer RGCs and less defined axon tracks
compared with the internal control. There was an average
significant loss of 28.12% (63.2, n ¼ 8) of RGCs compared with
the internal control. Based on cresyl violet and anti-Thy 1.1
results, the loss of cells in the RGC layer due to hypertonic
injections of NaCl into the rat’s episcleral veins are hypothesized to be primarily RGCs.
Although it is likely that Thy 1.1-labeled RGCs in the RGC
layer, other studies have demonstrated that Thy 1.1 expression
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can be downregulated by RGC alterations without actual RGC
death.22,23 To address this issue, glaucoma-inducing experiments were repeated using the specific RGC nuclear marker
Brn3a18,19 to determine whether results obtained using the
RGC nuclear marker coincide with results obtained using Thy
1.1. The Brn3 family of POU-domain transcription factors has
been shown to play important roles in differentiation, survival,
and axonal elongation24 and have emerged as a reliable marker
for RGCs in mice and rats.25,26
Figure 6 illustrates a typical example obtained when the
nuclear marker, Brn3a, was used to label RGCs. In this
example, the left eye was untreated and the right eye was
injected with 2 M hypertonic saline to induce glaucoma-like
conditions. One month following NaCl injection, the animal
was killed, retinas were removed while maintaining eye
orientation and flatmounted for processing with anti-Brn3a.
Figure 6 (left panel) represents an image obtained from an
untreated control retina 4 mm from the ONH from the nasal
quadrant, while Figure 6 (right panel) represents an image
obtained from the same region in the right eye 1 month after
NaCl injection. As shown in this image, the hypertonic saline
injection resulted in significantly fewer RGCs. When labeled
with an antibody against Brn3a, there was an average
significant loss of 25.82% (65.1, n ¼ 5) of RGCs compared
with the internal control. This percent loss is statistically
similar to the 28.12% (63.2) loss of RGCs measured when antiThy 1.1 was used to label RGCs and supports the hypothesis
that both Thy 1.1 and Brn3a labeled a similar number of RGCs
in the rat retina.

An a7 nAChR Agonist Prevents Loss of RGCs
Previous studies from this laboratory using an in vitro
excitotoxic model on isolated rat RGCs have demonstrated
that the a7 nAChR agonist, PNU-282987, prevents the loss of
RGCs against glutamate-induced excitotoxity.11 The next
experiments were designed to determine if PNU-282987
provided neuroprotection against loss of RGCs in the in vivo
rat model. For these studies, various concentrations of PNU282987 were injected into the vitreous cavity of anesthetized
rats after standard LC/MSMS procedures were conducted to
verify that PNU-282987 could be detected in the retina after
intravitreal injection. For the LC/MSMS studies, retinas were
removed from euthanized Long Evans rats 1, 2, 4, 8, and 12
hours after intravitreal injections containing 5 lL of 10 lM, 100
lM, or 1 mM PNU-282987. Removed retinas were rinsed of any
residual PNU-282987, weighed, and analyzed for LC/MSMS
detection of PNU-282987.

FIGURE 5. Fluorescent labeling of RGCs. (A) Represents a left eye image of RGCs immunostained with an antibody against Thy 1.1 under control
untreated conditions 4 mm from the ONH. (B) Represents immunostained RGCs from the right eye of the same rat, from an equivalent position, 1
month after NaCl injection into the episcleral vein.
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FIGURE 6. Labeling of RGCs with anti-Brn3a. Left panel represents a left eye image of RGCs immunostained with an antibody against Brn3a under
control untreated conditions 4 mm from the ONH. Right panel represents immunostained RGCs from the right eye of the same rat, from an
equivalent position, 1 month after NaCl injection into the episcleral vein. Arrows are pointed to Brn3a-labeled cells.

Results from the LC/MSMS studies demonstrated that all
three doses of PNU-282987 could be detected in the retinas in
a dose-dependent manner. The results of these experiments are
summarized in Figure 7. The highest amount of PNU-282987
detected in the retina was recorded 2 hours after 100 lM PNU282987 was injected into the vitreous. Two hours after
application, LC/MSMS detected 3.1 ng PNU/g (60.65) in the
retina after 10 lM was injected, 5.25 ng PNU/g (60.48) after
100 lM was injected and 4.81 ng PNU/g (60.48) after 1 mM
was injected. Each of these values obtained 2 hours after
intravitreal injection was significantly different from all other
time intervals for each particular concentration. PNU-282987
detection was the lowest at 12 hours.
After providing evidence that PNU-282987 can be detected
in the rat retina after intravitreal injection, the next experiments were designed to determine if PNU-282987 provided
neuroprotection against loss of RGCs using the in vivo rat
glaucoma model. The right eye of each experimental rat was
intravitreally injected with 5 lL of 10 lM, 100 lM, or 1 mM
PNU-282987 1 hour before NaCl injection. Previous in vitro
studies,10,11 as well as preliminary in vivo time-dependent
studies, demonstrated that neuroprotective agents had to be
applied 1 to 2 hours before application of excessive glutamate
or NaCl injection into the episcleral veins for neuroprotection
to occur.
Figure 8 represents sample images obtained from one of
these experiments, where 5 lL of 100 lM PNU-282987 was
injected into the vitreous humor 1 hour before NaCl injection.
Figure 8A represents an image obtained from the untreated left
internal control eye 4 mm from the ONH in the temporal
quadrant, while Figure 8B represents an image obtained from
the right eye from the same rat and from the same retinal
region, where PNU-282987 was intravitreally injected before
NaCl injection into the episcleral veins. One month following
NaCl injection, eyes were harvested, processed for Thy 1.1
labeling, and RGC counts were compared to the internal
control eyes. As shown in Figure 8, intravitreal injection of 100
lM PNU-282987 into the vitreous cavity prevented the loss of
RGCs that normally occur due to the NaCl injection. Studies
performed using Brn3a to label RGC nuclei demonstrated
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similar results. If retinas were injected with 100 lM PNU282987 before hypertonic injection into the episcleral veins to
induce glaucoma-like conditions, the typical loss of RGC nuclei
associated with the hypertonic saline injections were significantly reduced by an average of 87.3% (65.6; n ¼ 3). This is

FIGURE 7. PNU-282987 detection in the rat retina. Retinas were
removed from animals after intravitreal injections of three different
concentrations of PNU-282987. Retinas were removed after different
periods of time following intravitreal injection of the a7 agonist. Each
bar represents the amount of PNU-282987 detected (ng PNU/g wet
tissue) under each condition. The open circle, solid circle, and star
indicate significance from all other time points using the same PNU282987 concentration. Each bar graph was generated from three
retinas. Error bars represent SEM.
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FIGURE 8. Neuroprotective effect of PNU-282987. (A) Represents a left eye image of RGCs immunostained with an antibody against Thy 1.1. under
control untreated conditions, 4 mm from the ONH. (B) To obtain the image, the right eye was intravitreally injected with 100 lM PNU-282987 1
hour before NaCl injection into the episcleral vein. The image shown in (B) was obtained from the same rat that produced (A), from an equivalent
retinal location, 1 month after NaCl injection.

significantly similar to the neuroprotective effect recorded
when PNU-282987 was intravitreally injected and cells were
labeled with anti-Thy 1.1.

NaCl Injections Increased IOP
As shown in the Table, besides a loss of RGCs, NaCl injection
into the episcleral veins also increased intraocular pressure.
IOP measurements were obtained from awake rats before and
after NaCl injection into the episcleral veins using the
tonometer (Mentor O & O, Inc.) according to the methods
outlined by Morrison et al.16 Before NaCl injection, IOP
measurements fluctuated between 10 and 13 mm Hg,
averaging 12.3 mm Hg (61.9, n ¼ 8). However, within 2
weeks following NaCl injection, the IOP began to increase.
One month after NaCl injection, there was a significant
increase in the average IOP measurement compared with the
average IOP measurement obtained from the internal controls.
One month following NaCl injection, the IOP measurements
ranged from 18 to 23 mm Hg, averaging 21.22 mm Hg (63.21).
In control experiments, IOP measurements were obtained
from untreated retinas and then 100 lM PNU-282987 was
intravitreally injected without performing the NaCl injection
insult. This was performed to demonstrate that it was not the
PNU-282987 intravitreal injection that caused an increase of
IOP. In six different retinas, there was no significant increase of
IOP from baseline levels after intravitreal injection of PBS (n ¼
3) or 100 lM PNU-282987 (n ¼ 3) if NaCl injections into
episcleral veins did not occur.
Figure 9 demonstrates the dose-response curve generated
when various concentrations of PNU-282987 between 0.1 and
1000 lM were intravitreally injected into rat eyes before NaCl
injections. One month after NaCl injection, significant neuro-

protection against RGC loss occurred if 5 lL of 10 lM PNU282987 was injected into the vitreous cavity, but maximal
neuroprotection occurred when 100 lM PNU-282987 was
used. The neuroprotective effect using 100 and 1000 lM PNU282987 was not significantly different. 100 lM PNU-282987
acted to prevent the loss of RGCs by an average of 96.22%
(614.2). The EC50 for the neuroprotective effect was
calculated to be 42 lM.
If PNU-282987’s neuroprotective effect is mediated through
activation of a7 nAChRs on rat RGCs, then a7 nAChR
antagonists should block the effect. To test this hypothesis,
additional experiments were performed where 5 lL of the a7
nAChR specific antagonist, MLA (10 lM), was injected into the
vitreous cavity of right eyes an hour before intravitreal
injection of PNU and 2 hours before NaCl injection into the
episcleral veins. The summary of these experiments are
illustrated in Figure 10. After injection of hypertonic saline
into the episcleral veins, there was an average RGC loss of
23.86% (66.68, n ¼ 28) 4 mm from the ONH. However, when
retinas were pretreated with the a7 nAChR agonist PNU282987, RGC loss was prevented. When MLA was injected
prior to the PNU agonist and prior to NaCl injection into the
episcleral veins, the neuroprotective effect of PNU was
eliminated and a significant loss of RGCs occurred, averaging

TABLE. Mean IOP Measurements Obtained Before and After Surgery to
Induce Glaucoma-Like Conditions
Left Control
Eyes, n ¼ 8
Baseline before surgery
1 wk postsurgery
2 wk postsurgery
3 wk postsurgery
4 wk postsurgery

12.6
13.8
14.3
12.6
13.6

Right Experimental
Eyes, n ¼ 8

(61.7)
(62.2)
(62.5)
(61.8)
(62.1)

* Represents significance from internal control.
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12.3
14.1
15.6
17.2
21.4

(61.9)
(62.9)
(61.7)
(61.5)*
(63.1)*

FIGURE 9. Dose-response effect of PNU-282987. Each data point
shown represents the average percent of RGC survival compared with
control untreated conditions using different concentrations of PNU282987. Different concentrations of PNU-282987 were injected into
the right eye of experimental rats 1 hour before NaCl injection. Animals
were killed 1 month later and the percent of RGC survival was
quantified. Data points were curve fit. Error bars represent SEM.
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the NaCl injection in the right eye. When comparing these two
experimental conditions, the retinas pretreated with 100 lM
PNU-282987 significantly increased RGC survival by an average
of 130.33% (612.72, n ¼ 6).

DISCUSSION

FIGURE 10. Summary of PNU-282987 experiments. Each bar graph
shown represents the average percent change in RGCs compared with
each animal’s internal untreated control eye. Sham experiments were
obtained where intravitreal injections consisted of PBS instead of PNU282987. Asterisk represents significance from the untreated control.
Error bars represent SEM.

20.23% (66.29, n ¼ 4). In sham experiments, 5 lL of PBS
vehicle was injected into the eye before the NaCl injection
instead of PNU-282987 to determine if the NaCl injection alone
was responsible for increased RGC survival. The sham
treatment had no significant effect on RGC survival and there
was significant loss of RGCs when PBS was substituted for the
a7 nAChR agonist. One month after PBS intravitreal injections
and NaCl injection designed to induce glaucoma-like conditions, RGC loss averaged 19.85% (65.72, n ¼ 4).
The next experiments were designed to directly measure
the neuroprotective effects of PNU-282987 on RGC survival in
the hypertonic injection glaucoma model. For these experiments, both rat eyes were injected with 2M NaCl to induce loss
of RGCs in both retinas, after 5 lL of 100 lM PNU-282987 was
injected intravitreally into the right eye only. As seen in Figure
11A, NaCl injection into the left eye resulted in fewer RGCs
and loss of defined axon tracks. However, as shown in Figure
11B, PNU-282987 prevented the loss of RGCs associated with

In this study, the neuroprotective effects of PNU-282987 was
analyzed to prevent the loss of RGCs mediated through a7
nAChRs in an in vivo rat model of glaucoma. Results from this
study demonstrated that: (1) injection of 2M NaCl into the
episcleral veins significantly reduced RGC density after 1
month, 4 mm from the ONH in the retinal ganglion cell layer;
and (2) when PNU-282987 was directly injected into the
vitreous humor before NaCl injection designed to induce
glaucoma-like conditions, it prevented loss of RGCs due to
hypertonic injections in a dose-dependent manner. The
maximal neuroprotective effect of PNU-282987 occurred when
100 lM PNU-282987 was injected into the vitreous cavity of
the eye before NaCl was injected into the episcleral veins and
recovered an average of 96% of RGCs normally lost due to the
NaCl injection when using Thy 1.1 and recovered a similar 87%
when the RGC nuclear marker was used.
Results from this study are in agreement with the
effectiveness of the episcleral injection of hypertonic saline
to produce glaucoma-like conditions to produce a decrease of
RGCs in the rat retina that has been reported in other
laboratories.16,27 This consistency demonstrates that the
methods used to induce glaucoma in rat retina are appropriate
to examine glaucoma-like conditions. Many other studies have
also linked glaucoma-like conditions in rodent models with an
increase of intraocular pressure.16,28
This study also revealed that there was a larger percentage
of RGCs present in the rat ganglion cell layer at 4 mm from the
ONH than was previously reported in mice. We found this
increase of RGCs to be higher than that reported for mice in all
four retinal quadrants, including the dorsal visual streak region.
In several mouse studies, several reports indicated that as many
as 56% to 59% of neurons in the ganglion cell layer were not
RGCs.20,21 However, in the rat, when cells were labeled with
antibodies against Thy 1.1 or the nuclear marker Brn3a, nearly
90% of cells were labeled 4 mm from the ONH. This may be
due to species differences that occur in rats,29–31 the age of the

FIGURE 11. PNU-282987 protects against loss of RGCs. The fluorescent images represented were obtained 1 month after hypertonic injections
were made into both eyes. (A) Image (left eye) represents the effect of hypertonic saline injection into the episcleral vein on RGC survival. (B) The
image shown was obtained from the same animal, from an equivalent retinal position after 5 lL of 100 lM PNU-282987 was injected into the right
eye before the hypertonic injections to induce glaucoma-like conditions. Both images were obtained 1 month following injections to induce
glaucoma-like conditions and were obtained 4 mm from the ONH.
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animals used in this study (3 months),32–34 or the different
procedures used for detecting cells in previous studies.29,35,36
The mechanism responsible for the loss of RGCs associated
with glaucoma-like conditions is still under investigation. A
number of studies have argued that excitotoxicity plays a role
at the onset of glaucoma,37 but different contributing
mechanisms are also likely to play a role in the progression
of the disease such as; oxidative stress by reactive species,
vascular dysregulation, cytoskeletal dysfunction, changes in
growth factor levels, genetic contributions, or other pathological pathways.37,38 In glaucoma however, it is accepted that the
primary risk factor associated with glaucoma is an increase of
intraocular pressure, leading to the degeneration of the optic
nerve and loss of vision, which is the ultimate result of
contributing factors.
Regardless of the mechanism involved in loss of RGCs
associated with glaucoma-like conditions, neuroprotection
against cell loss has been used as a therapeutic approach for
many neurodegenerative diseases. In this study, we analyzed
the neuroprotective effect of PNU-282987, an a7 nAChRspecific agonist, against RGC loss that was correlated with
NaCl injections into the episcleral veins. Quantification of RGC
neuroprotection using PNU-282987 demonstrated a clear dosedependent effect, which plateaued when 5 lL of 100 lM PNU282987 was injected into the vitreous cavity.
Activation of a7 nAChRs in the brain have also been linked
to neuroprotection against several neurodegenerative diseases.9,39 What are the physiological implications of a7 nAChR
mediated neuroprotection in the retina? Starburst amacrine
cells are a category of amacrine cells that release ACh onto
RGCs.40,41 Pharmacological and immunocytochemical studies
have provided evidence of a7 nAChRs on both large and small
RGCs.11 As a result, ACh should initiate neuroprotection in
RGCs as it can be released from displaced starburst amacrine
cells in the RGC layer42 to protect against a glaucomatous
insult or from the inner nuclear layer. It’s possible that
neuroprotection from these cholinergic cells are lost under
glaucoma-like conditions due to death of the displaced
amacrine cells and/or loss of ACh. However, it has been
shown that cholinergic amacrine cells aren’t lost in glaucomalike conditions.43 Therefore, other factors are likely responsible for the loss of neuroprotection normally provided by ACh
release. Alternate hypotheses include scenarios where the
naturally occurring neuroprotective defense mechanisms
provided by ACh are overwhelmed or that ACh release is
compromised in a glaucomatous environment and a reduction
in ACh release from amacrine cells contribute to the loss of
RGCs normally associated with glaucoma. If the release of ACh
from starburst amacrine cells is compromised under glaucomalike conditions, it would unveil a previously unknown
neuroprotective function of starburst amacrine cells in the
retina. Current studies are underway to investigate ACh release
from the rat glaucomatous retina to enhance our understanding of this possibility and to gain an understanding of different
neuroprotective mechanisms used in the retina.
The main risk factor associated with glaucoma is an increase
in IOP. All current therapies are designed to decrease IOP.
Currently the two main treatments for glaucoma are drugs or
surgery. Either applied topically or orally, drugs can be
administered to decrease the production of aqueous humor
or can increase the drainage of fluid to decrease the IOP.44 In
other instances, a surgical procedure can produce small holes
in the eye to drain the aqueous humor, or a laser can
manufacture holes through the trabecular meshwork. Although these treatments work to decrease intraocular pressure, in most cases, decreasing the IOP does not completely
stop the progression of the disease. In some cases, patients
with normal IOP still develop glaucoma and vision loss, which
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indicates that something other than increased IOP may be
causing the vision loss. Because of this, it may be advantageous
to use an alternate treatment that provides neuroprotection
against loss of RGCs in the retina in conjunction with current
treatments. This would represent a unique and different
strategy for treating glaucoma. However, there are limitations
attached to any new treatment strategy. For instance, previous
studies have demonstrated that ACh, nicotine and PNU-282987
had to be applied before inducing excitotoxicity or before NaCl
injections into the episcleral veins for neuroprotection to
occur.10,14 As a result, treatments using an a7 nAChR agonist
would act as a preventative measure for patients at high risk of
glaucoma based on age, genetics or race. A neuroprotective
treatment with an a7 nAChR agonist under these limitations
could be used regardless of IOP.
In conclusion, these data suggest that introduction of a7
nicotinic agonist, PNU-282987 into the eye, could significantly
reduce the loss of RGCs associated with glaucoma. These
results strengthen the strategy of developing a7 nAChR
agonists as a potential therapeutic treatment for glaucoma.
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